P284: Prophylactic medication for the prevention of endoscopic recurrence after ileocolonic resection in Crohn’s disease: a prospective study based on clinical risk stratificationECCO'22Year: 2022
Authors: Arkenbosch , J.H.(1);Beelen, E.M.J.(1);Dijkstra, G.(2);Romberg-Camps, M.(3);Duijvestein, M.(4);Hoentjen, F.(5);van der Marel, S.(6); Maljaars, P.W.J.(7);Jansen, S.(8);de Boer, N.K.(9);West, R.(10);Horjus, C.(11); Stassen, L.P.S.(12);van Schaik , F.(13);van Ruler, O.(14); Jharap, B.J.H.(15);Erler, N.E.(16);Doukas , M.(17); Ooms, A.H.A.G.(18);Kats-Ugurlu, G.(19);van der Woude, J.(1);De Vries, A.C.(1);
(1)Erasmus Medical Center Hospital, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands;(2)University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, The Netherlands;(3)Zuyderland Medical Center, Department of Gastroenterology and Hepatology, Sittard-Geleen, The Netherlands;(4)Amsterdam University Medical Centers- University of Amsterdam- AG&M Research Institute, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(5)Radboud University Medical Center, Department of Gastroenterology and Hepatology, Nijmegen, The Netherlands;(6)Haaglanden Medical Center, Department of Gastroenterology and Hepatology, The Hague, The Netherlands;(7)Leiden University Medical Center, Department of Gastroenterology and Hepatology, Leiden, The Netherlands;(8)Reinier de Graaf Groep, Department of Gastroenterology and Hepatology, Delft, The Netherlands;(9)Amsterdam University Medical Centers- Vrije Universiteit Amsterdam- AG&M Research Institute, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(10)Franciscus Gasthuis & Vlietland, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands;(11)Rijnstate Hospital, Department of Gastroenterology and Hepatology, Arnhem, The Netherlands;(12)Maastricht University Medical Center, Surgery, Maastricht, The Netherlands;(13)University Medical Center Utrecht, Gastroenterology and Hepatology, Utrecht, The Netherlands;(14)IJsselland Hospital, Surgery, Capelle aan den IJssel, The Netherlands;(15)Meander Medical Center, Department of Gastroenterology and Hepatology, Amersfoort, The Netherlands;(16)Erasmus Medical Center Hospital, Department of Biostatistics- Department of Epidemiology, Rotterdam, The Netherlands;(17)Erasmus Medical Center Hospital, Department of Pathology, Rotterdam, The Netherlands;(18)Pathan BV- Sint Franciscus Vlietland Groep, Department of Pathology, Rotterdam, The Netherlands;(19)University Medical Center Groningen, Department of Pathology, Groningen, The Netherlands;
P285: Longitudinal single cell transcription profiling of peripheral blood disentangles shared and biologic-specific patterns of early remission in active IBD patientsECCO'22Year: 2022
Authors: P. Bernardes, J.(1);Mishra, N.(1);Schulte-Schrepping, J.(2);Herresthal, S.(2);Tran, F.(1,3);Aden, K.(1,3);Beyer, M.(4);Schultze, J.(2);Rosenstiel, P.(1);
(1)Institute of Clinical Molecular Biology, Systems Immunology, Kiel, Germany;(2)Life & Medical Sciences LIMES Institute- Bonn University, Genomics & Immunoregulation, Bonn, Germany;(3)University Hospital Schleswig Holstein, Internal Medicine I, Kiel, Germany;(4)German Center for Neurodegenerative Diseases DZNE, Molecular Immunology in Neurodegeneration, Bonn, Germany;
P286: Sustained improvement in health-related quality of life outcomes in patients with Ulcerative Colitis with long-term tofacitinib treatment in the open-label extension study, OCTAVE OpenECCO'22Year: 2022
Authors: Biedermann, L.(1);Dubinsky, M.C.(2);Vermeire, S.(3);Fellmann, M.(4);Gardiner, S.(5);Hur, P.(5);Mundayat, R.(5);Panés, J.(6);Rubin, D.T.(7);
(1)University Hospital Zürich, Department of Gastroenterology and Hepatology, Zürich, Switzerland;(2)-, Icahn School of Medicine at Mount Sinai, New York- NY, United States;(3)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(4)-, Pfizer Switzerland AG, Zürich, Switzerland;(5)-, Pfizer Inc, New York- NY, United States;(6)Hospital Clínic de Barcelona- IDIBAPS- CIBERehd, Department of Gastroenterology, Barcelona, Spain;(7)-, University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago- IL, United States;
P288: Recurrence rates of advanced neoplasia after endoscopic or surgical resection in Inflammatory Bowel Disease patients: a retrospective cohort studyECCO'22Year: 2022
Authors: Derks, M.(1);te Groen, M.(1);Peters, C.P.(2);Dijkstra, G.(3);de Vries, A.C.(4);Römkens, T.E.(5);Horjus, C.S.(6);de Boer, N.K.(7);Nagtegaal, I.D.(8);Derikx, L.A.(1);Hoentjen, F.(1,9);
(1)Radboud University Medical Center, Inflammatory Bowel Disease Center- Department of Gastroenterology and Hepatology, Nijmegen, The Netherlands;(2)Amsterdam University Medical Centers- localtion AMC, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(3)Groningen University Medical Center, Department of Gastroenterology and Hepatology, Groningen, The Netherlands;(4)Erasmus Medical Center, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands;(5)Jeroen Bosch Hospital, Department of Gastroenterology and Hepatology, 's Hertogenbosch, The Netherlands;(6)Rijnstate Hospital, Department of Gastroenterology and Hepatology, Arnhem, The Netherlands;(7)Amsterdam University Medical Centers- location VUmc, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(8)Radboud University Medical Center, Department of Pathology, Nijmegen, The Netherlands;(9)University of Edmonton, Division of Gastroenterology- Department of Medicine, Edmonton, Canada;on behalf of the Dutch Initiative on Crohn and Colitis (ICC)
P289: Evaluation of the safety and effectiveness of direct-acting antiviral drugs in the treatment of hepatitis C in patients with inflammatory bowel disease: National multicenter study (ENEIDA registry). MIC project.ECCO'22Year: 2022
Authors: Martin Cardona, A.(1,2);Horta, D.(1,2);Florez-Diez, P.(3);Vela , M.(4);Mesonero, F.(5);Ramos Belinchón, C.(6);García, M.J.(7);Masnou, H.(8);de la Peña-Negro, L.(9);Suárez Ferrer, C.(10);Casanova, M.J.(11);Ortiz Durán, M.(12);Peña, E.(13);Calvet, X.(14);Fernández Prada, S.J.(15);González-Muñoza, C.(16);Piqueras, M.(17);Rodríguez-Lago, I.(18);Sainz, E.(19);Bas-Cutrina, F.(20);Manceñido Marcos, N.(21);Ojeda, A.(22);Orts, B.(23);Sicilia, B.(24);Domènech, E.(8);Esteve, M.(1,2);
(1)Hospital Universitari Mútua Terrassa, Digestive Diseases Department, Terrassa, Spain;(2)Centro de Investigación biomédica en red de enfermedades hepáticas y digestivas CIBERehd., Digestive Diseases Department, Barcelona, Spain;(3)H.U. Central de Asturias, Digestive Diseases Department, Oviedo, Spain;(4)H. Nuestra Sra. de la Candelaria, Digestive Diseases Department, Santa Cruz de Tenerife, Spain;(5)H. Ramón y Cajal, Digestive Diseases Department, Madrid, Spain;(6)H. Gregorio Marañón, Digestive Diseases Department, Madrid, Spain;(7)H. U. Marques de Valdecilla, Digestive Diseases Department, Santander, Spain;(8)H.U. Germans Trias i Pujol, Digestive Diseases Department, Badalona, Spain;(9)H.U. Bellvitge, Digestive Diseases Department, Hospitalet de Llobregat, Spain;(10)H. La Paz, Digestive Diseases Department, Madrid, Spain;(11)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-IP and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD., Digestive Diseases Department, Madrid, Spain;(12)H.U. Infanta Cristina, Digestive Diseases Department, Madrid, Spain;(13)Hospital Royo Villanova, Digestive Diseases Department, Zaragoza, Spain;(14)H. Parc Taulí, Digestive Diseases Department, Sabadell, Spain;(15)H.Río Hortega, Digestive Diseases Department, Valladolid, Spain;(16)H. de la Sta Creu i Sant Pau, Digestive Diseases Department, Barcelona, Spain;(17)Consorci Sanitari de Terrassa, Digestive Diseases Department, Terrassa, Spain;(18)Hospital Universitario de Galdakao and Biocruces Bizkaia Health Research Institute- Galdakao, Digestive Diseases Department, Bizkaia, Spain;(19)Althaia Xarxa Assistencial Universitària de Manresa, Digestive Diseases Department, Manresa, Spain;(20)H. General de Granollers, Digestive Diseases Department, Granollers, Spain;(21)H. Infanta Sofía, Digestive Diseases Department, Madrid, Spain;(22)H.G.U. Elche, Digestive Diseases Department, Elche, Spain;(23)Hospital General Universitario de Alicante, Digestive Diseases Department, Alicante, Spain;(24)Hospital Universitario de Burgos, Digestive Diseases Department, Burgos, Spain;on behalf of the ENEIDA registry of GETECCU.
P290: Therapeutic requirements in patients with Ulcerative Proctitis. Is it necessary immunosuppressive therapy in these patients?ECCO'22Year: 2022
Authors: Ferreiro Iglesias, R.(1);Porto Silva, M.S.(1);Marín, S.(2);Casanova, M.J.(3);Mañosa, M.(4);González-Muñoza, C.(5);de Francisco, R.(6);Caballol, B.(7);Arias, L.(8);Piqueras, M.(9);Zabana , Y.(10);Rivero, M.(11);Calvet, X.(12);Mesonero, F.(13);Varela Trastoy, P.(14);Busta Nistal, R.(15);Gomez Perosanz, R.(16);Vega, P.(17);Gonzalez Vivo, M.(18);Iborra, M.(19);Jimenez Marquez, L.(20);Madero, L.(21);Rodríguez-Lago, I.(22);Rodriguez Gonzalez , M.(23);Vera, I.(24);Ponferrada Diaz, A.(25);Vela, M.(26);Torrealba, L.(27);Van Domselaar, M.(28);Iglesias , E.(2);P. Gisbert, J.(3);Calafat, M.(4);García-Planella, E.(5);Perez-Martinez, I.(6);Ricart, E.(7);Sicilia , B.(8);Mena, R.(9);Nieto, L.(1);Domenech, E.(4);Barreiro-de Acosta, M.(1);
(1)Hospital Clinico Universitario de Santiago. Fundación Instituto de Investigación Sanitaria de Santiago de Compostela IDIS, Gastroenterology Department, Santiago, Spain;(2)UCO/IMIBIC/Hospital Universitario Reina Sofía, Digestive System Service, Córdoba, Spain;(3)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-IP and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Gastroenterology, Madrid, Spain;(4)Hospital Universitari Germans Trias i Pujol. Badalona.Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Gastroenterology and Hepatology Department, Badalona, Spain;(5)Hospital Sant Creu I Sant Pau, Gastroenterology and Hepatology Department., Barcelona, Spain;(6)Hospital Universitario Central de Asturias, Gastroenterology Department, Oviedo, Spain;(7)IDIBAPS- CIBER-EHD- Hospital Clínic, Servei de Gastroenterologia- Barcelona- Spain, Barcelona, Spain;(8)Hospital Universitario de Burgos, Gastroenterology Department, Burgos, Spain;(9)Consorci Sanitari de Terrassa CST, Gastroenterology Department, Barcelona, Spain;(10)Hospital Mútua de Terrassa HMT. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd., Gastroenterology Department, Barcelona, Spain;(11)Hospital Universitario Marqués de Valdecilla Instituto de Investigación Marqués de Valdecilla IDIVAL, Gastroenterology Department, Santander, Spain;(12)Corporació Sanitària Universitaria Parc Taulí. Universistat Autònoma de Barcelona. CIBEREHD. Instituto de Salud Carlos III. Madrid-, Sabadell Department de Medicina, Sabadell, Spain;(13)Hospital Universitario Ramón y Cajal, Gastroenterology Department, Madrid, Spain;(14)Hospital Universitario de Cabueñes, Gastroenterology Department, Gijon, Spain;(15)Hospital Clínico Universitario de Valladolid, Gastroenterology Department, Valladolid, Spain;(16)Hospital Universitario Fundación Alcorcón, Gastroenterology Department, Madrid, Spain;(17)Hospital Clinico Universitario de Ourense, Gastroenterology Department, Gastroenterology Department, Spain;(18)Hospital del Mar- Barcelona. IMIM Hospital del Mar Medical Research Institute, Servei de Digestiu, Barcelona, Spain;(19)Hospital Universitario y Politécnico La Fe de Valencia, Gastroenterology Department, Valencia, Spain;(20)Hospital Universitario de Fuenlabrada, Gastroenterology Department, Madrid, Spain;(21)Hospital General Universitario de Alicante, Gastroenterology Department, Alicante, Spain;(22)Hospital Universitario de Galdakao- Biocruces Bizkaia Health Research Institute- Galdakao, Gastroenterology Department, Bilbao, Spain;(23)Hospital de Ciudad Real, Gastroenterology Department., Ciudad Real, Spain;(24)Hospital Universitario Puerta de Hierro, Gastroenterology Department, Madrid, Spain;(25)Hospital Universitario Infanta Leonor, Gastroenterology Department, Madrid, Spain;(26)Hospital Nuestra señora de la Candelaria, Gastroenterology Department, Tenerife, Spain;(27)Hospital Dr. Josep Treuta-, Gastroenterology Department, Girona, Spain;(28)Hospital Universitario de Torrejón, Gastroenterology Department, Madrid, Spain;Consortium of the ENEIDA Project of GETECCU
P291: Effect of the preconception steroid-free remission period on disease activity during pregnancy and birth outcomes in women with Ulcerative Colitis: a retrospective cohort studyECCO'22Year: 2022
Authors: Ikeda, A.(1);Kunisaki, R.(1);Aoki, S.(2);Yaguchi, K.(1);Asami, S.(1);Furusawa, K.(1);Atsusaka, R.(1);Azuma, D.(1);Tsunoda, S.(1);Fujii, K.(1);Nishida, D.(1);Madarame, A.(1);Nishio, M.(1);Ogashiwa, T.(1);Nakamori, Y.(1);Fuse, M.(1);Daibo, S.(1);Araki, K.(1);Kimura, H.(1);Suzuki, R.(3);Go, H.(4);Saigusa, Y.(4);Maeda, S.(5);
(1)Yokohama City University Medical Centre, Inflamatory Bowel Disease Centre, Yokohama, Japan;(2)Yokohama City University Medical Centre, Perinatal Centre for Maternity and Neonates, Yokohama, Japan;(3)Kannai-Suzuki Clinic, Inflammatory bowel disease, Yokohama, Japan;(4)Yokohama City University Graduate School of Medicine, Biostatistics, Yokohama, Japan;(5)Yokohama City University Graduate School of Medicine, Gastroenterology, Yokohama, Japan;
P292: Association of golimumab trough concentrations during maintenance with endoscopic and histologic remission in patients with ulcerative colitis.ECCO'22Year: 2022
Authors: Taxonera Samso, C.(1);Fernández-Aceñero, M.J.(2);Olivares, D.(1);Calvo, M.(3);Casis, B.(4);Bermejo, F.(5);López Serrano, P.(6);Iborra, M.(7);Mesonero, F.(8);Boscá Watts, M.(9);Díaz del Arco, C.(2);Vera, I.(3);Olivares, S.(4);Alba, C.(1);
(1)Hospital Clínico San Carlos, IBD Unit- Department of Gastroenterology, Madrid, Spain;(2)Hospital Clínico San Carlos, Pathology, Madrid, Spain;(3)Hospital Universitario Puerta de Hierro, Gastroenterology, Madrid, Spain;(4)Hospital Universitario 12 de Octubre, Gastroenterology, Madrid, Spain;(5)Hospital Universitario Fuenlabrada, Gastroenterology, Madrid, Spain;(6)Hospital Universitario Fundación Alcorcón, Gastroenterology, Madrid, Spain;(7)Hospital Universitario La Fe, Gastroenterology, Valencia, Spain;(8)Hospital Universitario Ramón y Cajal, Hospital Universitario Ramón y Cajal, Madrid, Spain;(9)Hospital Clínico Universitario de Valencia, Gastroenterology, Valencia, Spain;
P293: Insights from patients with Ulcerative Colitis on disease burden: Findings from a real-world survey in EuropeECCO'22Year: 2022
Authors: BurischPhD, J.(1,2);Hart, A.(3);Oortwijn, A.(4);Khalid, J.M.(4);Hennessy, F.(5);Knight, H.(5);Meadows, R.(5);Patel, H.(6);Armuzzi, A.(7);
(1)Hvidovre University Hospital- University of Copenhagen, Gastrounit- Medical division, Hvidovre, Denmark;(2)Hvidovre Hospital, Copenhagen Center for Inflammatory Bowel Disease in Children Adolescents and Adults, Hvidore, Denmark;(3)St Mark’s Hospital, IBD Unit, Harrow, United Kingdom;(4)Galapagos, Nv, Leiden, The Netherlands;(5)Adelphi, Real World, Bollington, United Kingdom;(6)Galapagos, Nv, Mechelen, Belgium;(7)Fondazione Policlinico Universitario A. Gemelli IRCCS, IBD Center, Rome, Italy;
P294: On the way to disease control: Fatigue as part of a novel composite endpoint in an analysis of a prospective open label observation trialECCO'22Year: 2022
Authors: Tran, F.(1,2);Nikolaus, S.(1);Schrinner, F.(2);Kümpers, J.(1);Lessing, A.(1);Lintner, J.(1);Lessing, M.(1);Sievers, L.K.(1,2);Rosenstiel, P.(2);Aden, K.(1,2);Franke, A.(2);Schreiber, S.(1,2);
(1)University Medical Center- Schleswig-Holstein- Kiel Campus, Department for Internal Medicine I, Kiel, Germany;(2)University Medical Center- Schleswig-Holstein- Kiel Campus, Institute of Clinical Molecular Biology, Kiel, Germany;
P295: Proctitis during Crohn's disease, would it be a factor in the sustainability of anoperineal fistulas ?ECCO'22Year: 2022
Authors: Mtir, M.(1);Hassine, H.(1);Kahlaoui, F.(1);Cherif, D.(1);Tlili, R.(1);Kchir, H.(1);Maamouri, N.(1);
(1)La Rabta hospital, department of gastro-enterology B, tunis, Tunisia;
P297: Treatment of patients with complex perianal Crohn's disease with darvadstrocel: a single-institution real life experience.ECCO'22Year: 2022
Authors: BorruelPhD, N.(1);Martí, M.(2);Armario, D.(3);Ibarz, A.(1);Robles, V.(1);Herrera, C.(1);Mayorga, L.(1);Pérez, Z.(1);Alonso, C.(4);Elena, C.(1);Planes, M.(3);Oller, E.(1);Espín, E.(5);Casellas, F.(1);
(1)Hospital Vall d'Hebron, Crohn's and colitis Attention Unit. Digestive System Research Unit., Barcelona, Spain;(2)Hospital Vall d'Hebron, Colorectal Surgery Unit. Surgery Department, Barcelona, Spain;(3)Hospital Vall d'Hebron, Department of Radiology, Barcelona, Spain;(4)Hospital Vall d'Hebron, Department of Pharmacy, Barcelona, Spain;(5)Hospital Vall d'Hebron, Colorrectal Surgery Unit. Surgery Department, Barcelona, Spain;
P298: Pregnancy in Crohn's and Colitis - Observations, Levels and Outcomes Extension (PICCOLO-X) Study: Biological therapy reduces faecal calprotectin and the need for corticosteroids in pregnant women with Inflammatory Bowel DiseaseECCO'22Year: 2022
Authors: Prentice, R.(1);Wright, E.(2);Flanagan, E.(2);Goldberg, R.(1);Prideaux, I.(1);Ross, A.(2);Burns, M.(1);Bell, S.(1);
(1)Monash Medical Centre, Gastroenterology, Melbourne, Australia;(2)St Vincent's Hospital Melbourne, Gastroenterology, Melbourne, Australia;Pregnancy in Crohn's and Colitis: Observations Levels and Outcomes Study Group
P299: Prediction model for steroid-free clinical remission with vedolizumab at week 22 in patients with Ulcerative Colitis: Machine learning using clinical data at baselineECCO'22Year: 2022
Authors: Miyoshi, J.(1);Maeda, T.(2);Matsuoka, K.(3);Saito, D.(1);Morikubo, H.(1);Matsuura, M.(1);Tamura, S.(2);Hisamatsu, T.(1);
(1)Kyorin University School of Medicine, Department of Gastroenterology and Hepatology, Mitaka-shi, Japan;(2)Gifu University, Department of Electrical- Electronic & Computer Engineering- Faculty of Engineering, Gifu-shi, Japan;(3)Toho University Sakura Medical Center, Division of Gastroenterology and Hepatology- Department of Internal Medicine, Sakura-shi, Japan;
P300: Very early onset Inflammatory Bowel Diseases: Review of the Genoa-Messina joint clinical experience. Therapeutic approach: Part IIECCO'22Year: 2022
Authors: Gramaglia, S.M.C.(1);Cucinotta, U.(1);Dipasquale, V.(1);Serena, A.(2);Gandullia, P.(2);Romano, C.(1);
(1)Pediatric Gastroenterology and Cystic Fibrosis Unit, Department of Human Pathology in Adulthood and Childhood @G. Barresi@- University of Messina, Messina, Italy;(2)Institute 'Giannina Gaslini'- Genoa- Italy, Pediatric Gastroenterology and Endoscopy Unit, Genova, Italy;
P301: Relapse rates after withdrawal of thiopurines in patients with Inflammatory Bowel Disease.ECCO'22Year: 2022
Authors: Ranjan, M.K.(1);Vuyyuru, S.K.(1);Kante, B.(1);Kumar, P.(1);Mundhra, S.K.(1);Golla, R.(1);Sharma, R.(2);Sahni, P.(3);Das, P.(4);Makharia, G.(1);Kedia, S.(1);Ahuja, V.(1);
(1)All India Institute of Medical Sciences, Department of Gastroenterology and Human Nutrition, New Delhi, India;(2)All India Institute of Medical Sciences, Department of Radio Diagnosis, New Delhi, India;(3)All India Institute of Medical Sciences, Department of Gastrointestinal Surgery, New Delhi, India;(4)All India Institute of Medical Sciences, Department of Pathology, New Delhi, India;
P302: Malignancy surveillance in patients with primary sclerosing cholangitis and Inflammatory Bowel Disease – keeping up with international guidelines? A Norwegian cohort studyECCO'22Year: 2022
Authors: Tønjum, T.K.(1);Anisdahl, K.(1,2);Folseraas, T.(3);Midgard, H.(2);Høivik, M.L.(1,2);
(1)University of Oslo, Institute of Clinical Medicine, Oslo, Norway;(2)Oslo University Hospital, Department of Gastroenterology, Oslo, Norway;(3)Oslo University Hospital Rikshospitalet, Section of Gastroenterology & the Norwegian PSC Research Centre- Department of Transplantation Medicine- Division of Surgery- Inflammatory Medicine and Transplantation, Oslo, Norway;
P303: Biologic Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease: Are we aiming high?ECCO'22Year: 2022
Authors: Robertson, A.(1);Hawkins, I.(1);Wilkinson, S.(2);Patel, R.(3);
(1)Lakes District Health Board, House Officer, Rotorua, New Zealand;(2)Lakes District Health Board, Gastroenterology Nurse Specialist, Rotorua, New Zealand;(3)Lakes District Health Board, Consultant Gastroenterologist, Rotorua, New Zealand;
P304: Intensified versus conventional infliximab induction in acute severe steroid-refractory Ulcerative ColitisECCO'22Year: 2022
Authors: Pedro, J.(1);Coelho Rodrigues, I.(1);Botto, I.(1);Fernandes, S.(1);Bernardo, S.(1);Gonçalves, A.R.(1);Moura Santos, P.(1);Valente, A.(1);Correia, L.(1);Tato Marinho, R.(1);
(1)Centro Hospitalar Lisboa Norte, Gastrenterology, Lisboa, Portugal;
